Within the diagnostics business, Abbott's core laboratory sales grew 4 percent but its other diagnostic segments were down year over year.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
Beckman Coulter got regulatory clearance for three in vitro diagnostic products, including its DxH 520 hematology analyzer for low-volume clinical labs.
The biomarkers — ubiquitin carboxyl terminal hydrolase-L1 and glial fibrillary acidic protein — can be detected in blood soon after a brain injury.
The firm has expansive plans, including a possible launch of 40 different types of tests. It currently plans to launch a liver function test in the US this summer.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
Regional Medical Laboratory, a commercial reference lab, is using the Alinity next-gen immunoassay system in the face of growing test volumes and a shortage of trained labor.
The Army previously awarded Abbott $11.3 million to develop a TBI test. Abbott has worked with DoD since 2014 to develop tests to help evaluate potential concussions.
The firm said that its rapid flu detection platform helps reduce the subjectivity of interpreting test results and can be used in a broad range of healthcare settings.